Microba Life Sciences logo

Microba Life Sciences(ASX) MAP

Market CapA$36.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-85%
5 YearN/A
1 Year-41%
1 Month-9%
A$0.05
+2.00%
+0.00Today
Microba Life Sciences last closing stock price
MetricPriceDate
Last closeAUD 0.052026-10-09
Microba Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.08%AUD 0.052026-10-02
1 month-8.93%AUD 0.062026-09-09
3 month+24.39%AUD 0.042026-07-10
Year to date-32.89%AUD 0.082025-12-31
1 year-41.38%AUD 0.092025-10-09
3 year-82.11%AUD 0.292023-10-10
Since inception-84.56%AUD 0.332022-04-05

Microba Life Sciences Financials at a Glance

Market Cap

A$36.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$30.43M

Net Income (TTM)

-A$35.66M

EPS (TTM)

-A$0.03

P/E Ratio

-1.48

Dividend

A$0.00

Beta (Volatility)

-0.10 (Low)

Price

A$0.05

Volume

21,074

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.05

52-Week Range

A$0.04 - A$0.11

Estimated Earnings Date

Mar 3, 2027

MAP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Microba Life Sciences

Microba Life Sciences Limited, established in Brisbane, Australia, specializes in advanced microbiome testing and analytical services. The company serves clinicians, individual consumers, and research customers across key international markets, delivering innovative solutions rooted in human gut microbiome science.

Products and Services
  • Microbiome testing for clinical and consumer applications
  • Pathology, therapeutic, and diagnostic solutions
  • Data-driven therapeutics platform for microbial cell therapies
Growth Outlook
  • Expansion into international markets, including Europe and the UAE
  • Innovative therapies targeting inflammatory bowel disease and cancer
  • Increasing demand for microbiome-related health solutions
Financial Highlights
  • Recent quarterly revenue of 7.44 million AUD, showing growth potential
  • Trailing twelve months (TTM) revenue of 29.5 million AUD
  • Cash reserves of 7.95 million AUD, supporting ongoing operations
Microba Life Sciences Limited is positioned in the healthcare sector, focusing on the burgeoning field of microbiome research. The company’s innovative approach to microbiome testing and therapeutic solutions is gaining traction in various international markets. With a robust product offering and a strategic growth outlook, Microba aims to capitalize on the increasing awareness and demand for microbiome health solutions. Recent financial data indicates a solid revenue stream, which, combined with significant cash reserves, provides a foundation for future growth and development.
AI Generated • Sep 24, 2026

Industry

Healthcare Providers and Services

CEO

Luke Reid, PhD

Headquarters

Brisbane, QLD 4000, AU

MAP Financials

Key Financial Metrics (TTM)

Gross Margin

-79.54%

Operating Margin

-137.58%

Net Income Margin

-140.40%

Return on Equity

-75.96%

Return on Capital

-71.28%

Return on Assets

-52.05%

Earnings Yield

-67.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$36.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

717.12M

Volume

21.07K

Avg. Volume

294.57K

Financials (TTM)

Gross Profit

-A$4.30M

Operating Income

-A$39.14M

EBITDA

-A$36.07M

Operating Cash Flow

-A$24.38M

Capital Expenditure

-A$566.73K

Free Cash Flow

-A$24.95M

Cash & ST Invst.

A$7.95M

Total Debt

A$4.11M

Microba Life Sciences Performance Analysis

Microba Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 5,420,13615.6%
20242024-06-30AUD 12,090,055123.1%
20252025-06-30AUD 15,669,08929.6%
20262026-06-30AUD 14,758,461-5.8%
Microba Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30-8.3%
Q42025-06-30-6.2%
Q22025-12-31-3.5%
Q42026-06-301.6%
Microba Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.04-3.5%
20242024-06-30AUD -0.0527.6%
20252025-06-30AUD -0.03-31.5%
20262026-06-30AUD -0.033.6%
Microba Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3032.3%
Q42025-06-30-59.4%
Q22025-12-3111.8%
Q42026-06-308.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$7.44M

-15.6%

Gross Profit

-A$5.16M

-23.6%

Gross Margin

-69.40%

N/A

Market Cap

A$36.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$457.16K

N/A

Employees

80

N/A

Net Income

-A$10.17M

-20.3%

EBITDA

-A$7.20M

-8.8%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$7.95M

-62.0%

Total Debt

A$4.11M

+159.7%

Accounts Receivable

A$3.21M

-60.4%

Inventory

A$2.22M

-1.3%

Long Term Debt

A$792.18K

+112.3%

Short Term Debt

A$3.31M

+174.3%

Return on Assets

-52.05%

N/A

Return on Invested Capital

-70.94%

N/A

Free Cash Flow

-A$6.72M

-1.0%

Operating Cash Flow

-A$6.67M

-67.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EYE.AXNova Eye Medical Limited
A$0.14+0.00%
BDX.AXBCAL Diagnostics Limited
A$0.09+0.00%
NXS.AXNext Science Limited
A$0.15+0.00%
HMD.AXHeraMED Limited
A$0.04-7.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About MAP

What is the current price of Microba Life Sciences?

Microba Life Sciences is trading at A$0.05 per share.

What is the 52-week range for Microba Life Sciences?

Over the past 52 weeks, Microba Life Sciences has traded between A$0.04 and A$0.11.

How much debt does Microba Life Sciences have?

As of the most recent reporting period, Microba Life Sciences reported total debt of A$4.11M.

How much cash does Microba Life Sciences have on hand?

Microba Life Sciences reported A$7.95M in cash and cash equivalents in its most recent financial results.

What is Microba Life Sciences’s dividend yield?

Microba Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.